Meloxicam and Erbitux drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Meloxicam (meloxicam) and Erbitux (cetuximab). Common drug interactions include dermatitis acneiform among females and cerebral infarction among males.

The phase IV clinical study analyzes what interactions people have when they take Meloxicam and Erbitux. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Meloxicam?

Meloxicam has active ingredients of meloxicam. It is often used in arthritis. eHealthMe is studying from 68,017 Meloxicam users. Check the latest studies of Meloxicam.

What is Erbitux?

Erbitux has active ingredients of cetuximab. It is often used in cancer. eHealthMe is studying from 19,276 Erbitux users. Check the latest studies of Erbitux.

On Aug, 11, 2026

18 people who take Meloxicam and Erbitux together, and have interactions are studied.

Meloxicam and Erbitux drug interactions.

What are the common drug interactions of Meloxicam and Erbitux, by gender? *:

female:

Dermatitis acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis)
Alanine aminotransferase increased
Blood alkaline phosphatase increased
Blood calcium increased
Blood urea increased
Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
Gamma-glutamyltransferase increased
Infusion related reaction
Iridocyclitis (inflammation of the iris and ciliary body of the eye)
Pleural effusion (water on the lungs)

male:

Cerebral infarction (less blood supply to brain resulting tissue damage)
Jaundice cholestatic
Disorientation (disability in which the senses of time, direction, and recognition of people and places)
Fall
Nausea (feeling of having an urge to vomit)
Oral pain
Tongue haemorrhage (bleeding from tongue)
Weight decreased
Azotaemia (excess of urea or other nitrogenous compounds in the blood)
Bladder cancer

What are the common drug interactions of Meloxicam and Erbitux, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Cerebral infarction (less blood supply to brain resulting tissue damage)
Jaundice cholestatic

50-59:

Acne (skin problems that cause pimples)
Cheilitis (infection of lips)
Paronychia (infection in the tissues adjacent to a nail on a finger or toe)
Pruritus (severe itching of the skin)
Seborrhoeic dermatitis (a common, inflammatory skin condition that causes flaky, white to yellowish scales to form on oily areas such as the scalp)
Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Dermatitis bullous (inflammation of the skin characterized by the presence of bullae which are filled with fluid)
Dysphagia (a condition in which swallowing is difficult or painful)
Gastric perforation (hole in stomach)
Lymphocyte count decreased

60+:

Blood magnesium decreased
Blood pressure diastolic decreased
Azotaemia (excess of urea or other nitrogenous compounds in the blood)
Bladder cancer
Blood alkaline phosphatase increased
Blood calcium increased
Blood urea increased
Blood urine present
Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
Dyspepsia (indigestion)

What are the existing conditions these people have? *

Gastroesophageal Cancer: 5 people, 27.78%
High Blood Pressure: 5 people, 27.78%
Colon Cancer: 4 people, 22.22%
Vena Cava Thrombosis (clotting of the blood in large vein carrying deoxygenated blood into the heart): 3 people, 16.67%
Depression: 3 people, 16.67%
Gastroenteritis (inflammation of stomach and intestine): 3 people, 16.67%
Gastrointestinal Candidiasis (fungal infection of gastrointestinal tract): 3 people, 16.67%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 3 people, 16.67%
Gallstones (stone formation by bile component): 3 people, 16.67%
Gastric Ulcer (stomach ulcer): 3 people, 16.67%

* Approximation only. Some reports may have incomplete information.

Do you take Meloxicam and Erbitux?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously